Clinical Study
Tocilizumab or TCQ: A Study Drug for Pediatric Patients with COVID-19
Tocilizumab or TCQ is a study drug to help pediatric patients hospitalized with COVID-19. Research is needed to learn if it is safe and effective for these patients. The information we gain may aid futures patients.
For more information contact:
Evan Heller
evan.heller@hsc.utah.edu
801-587-6293
IRB#: IRB_00150759
| PI: Kevin Watt
| Department: PEDIATRICS
| Approval Date: 2022-06-22 06:00:00
Study Categories: COVID-19 Studies
| Specialties: Infectious Diseases
Who can participate?
Gender: All
Age: All Ages
Volunteers: Volunteers with special conditions
Location: In Person
COVID-19 Study
Inclusion Criteria:
- Must be hospitalized with COVID-19
- 18 years old or younger
Exclusion Criteria:
- Known allergic reaction to the study medicine
- Tuberculosis
- Pregnant
Will I be paid for my time?
Yes